<?xml version='1.0' encoding='utf-8'?>
<document id="26255619"><sentence text="Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines." /><sentence text="Obatoclax is a pan-Bcl-2 inhibitor with promising efficacy, especially when combined with other antineoplastic agents" /><sentence text=" Pharmacokinetic drug-drug interactions can occur systemically and at the level of the tumour cell" /><sentence text=" Thus, this study scrutinised the interaction potential of obatoclax in vitro" /><sentence text="" /><sentence text="Obatoclax was screened for P-gp inhibition by calcein assay, for breast cancer resistance protein (BCRP) inhibition by pheophorbide A assay and for inhibition of cytochrome P450 isoenzymes (CYPs) by commercial kits"><entity charOffset="119-133" id="DDI-PubMed.26255619.s6.e0" text="pheophorbide A" /></sentence><sentence text=" Induction of mRNA of drug-metabolising enzymes and drug transporters was quantified in LS180 cells via real-time polymerase chain reaction and involvement of nuclear receptors was assessed by reporter gene assays" /><sentence text=" Proliferation assays were used to assess whether obatoclax retains its efficacy in cell lines overexpressing BCRP, P-glycoprotein (P-gp) or multidrug resistance-associated protein 2 (MRP2)" /><sentence text="" /><sentence text="Obatoclax induced the mRNA expression of several genes (e" /><sentence text="g" /><sentence text=" CYP1A1, CYP1A2 and ABCG2 (five to seven-fold) through activation of the aryl hydrocarbon receptor in the nanomolar range"><entity charOffset="73-89" id="DDI-PubMed.26255619.s12.e0" text="aryl hydrocarbon" /></sentence><sentence text=" Obatoclax inhibits P-gp, BCRP and some CYPs at concentrations exceeding plasma levels" /><sentence text=" P-gp, MPR2 or BCRP overexpression did not influence the efficacy of obatoclax" /><sentence text="" /><sentence text="Obatoclax retains its efficacy in cells overexpressing P-gp, MRP2 or BCRP and might act as a perpetrator drug in interactions with drugs, for example being substrates of CYP1A2 or BCRP" /><sentence text="" /></document>